一种综合的计算机免疫遗传学分析平台为 COVID-19 的血清学和疫苗靶点提供了深入了解。
An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets.
机构信息
Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK.
出版信息
Genome Med. 2021 Jan 7;13(1):4. doi: 10.1186/s13073-020-00822-6.
During COVID-19, diagnostic serological tools and vaccines have been developed. To inform control activities in a post-vaccine surveillance setting, we have developed an online "immuno-analytics" resource that combines epitope, sequence, protein and SARS-CoV-2 mutation analysis. SARS-CoV-2 spike and nucleocapsid proteins are both vaccine and serological diagnostic targets. Using the tool, the nucleocapsid protein appears to be a sub-optimal target for use in serological platforms. Spike D614G (and nsp12 L314P) mutations were most frequent (> 86%), whilst spike A222V/L18F have recently increased. Also, Orf3a proteins may be a suitable target for serology. The tool can accessed from: http://genomics.lshtm.ac.uk/immuno (online); https://github.com/dan-ward-bio/COVID-immunoanalytics (source code).
在 COVID-19 期间，已经开发出了诊断血清学工具和疫苗。为了在疫苗接种后监测环境中为控制活动提供信息，我们开发了一个在线“免疫分析”资源，该资源结合了表位、序列、蛋白质和 SARS-CoV-2 突变分析。SARS-CoV-2 的刺突蛋白和核衣壳蛋白都是疫苗和血清学诊断的靶标。使用该工具，核衣壳蛋白似乎不是血清学平台的最佳靶标。刺突蛋白 D614G（和 nsp12 L314P）突变最为常见（>86%），而刺突蛋白 A222V/L18F 最近有所增加。此外，Orf3a 蛋白可能是血清学的合适靶标。该工具可从以下网址访问：http://genomics.lshtm.ac.uk/immuno（在线）；https://github.com/dan-ward-bio/COVID-immunoanalytics（源代码）。
Zotero 插件